Morgan Stanley Maintains Underweight on Avanos Medical, Lowers Price Target to $36
Morgan Stanley maintains Avanos Medical (NYSE:AVNS) with a Underweight and lowers the price target from $37 to $36.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Avanos Medical Q3 EPS $0.25 Misses $0.30 Estimate, Sales $184.10M Miss $185.34M Estimate
Avanos Medical (NYSE:AVNS) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.30 by 16.67 percent. This is a 19.05 percent increase over earnings of $0.21 per share from the
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 14)
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 13)
Morgan Stanley Maintains Underweight on Avanos Medical, Lowers Price Target to $41
Morgan Stanley analyst Drew Ranieri maintains Avanos Medical (NYSE:AVNS) with a Underweight and lowers the price target from $45 to $41.
Stephens & Co. Downgrades Avanos Medical to Equal-Weight, Lowers Price Target to $45
Stephens & Co. analyst Chris Cooley downgrades Avanos Medical (NYSE:AVNS) from Overweight to Equal-Weight and lowers the price target from $60 to $45.